Results 141 to 150 of about 53,113 (297)

Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis

Hepatology Research, EarlyView.
ABSTRACT Background Hepatocellular carcinoma (HCC) with Vp4 portal vein tumor thrombosis (PVTT) has an extremely poor prognosis, and evidence for effective systemic therapy is limited. Preclinical studies suggest that hypofractionated radiation therapy (HFRT) may enhance immune checkpoint inhibitor (ICI) efficacy through immunogenic cell death and ...
Masahiko Tameda, Hideaki Tanaka, Yutaka Toyomasu, Mizuki Kawachi, Hirono Owa, Mone Tsukimoto, Yasuyuki Tamai, Naoto Fujiwara, Ryuta Shigefuku, Suguru Ogura, Yoshihito Nomoto, Hayato Nakagawa   +11 more
wiley   +1 more source

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. [PDF]

, 2019
BackgroundWe previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy.
Demaria, Sandra, Dixit, Neha, Evensen, Erik, Formenti, Silvia C, Goldberg, Judith D, Hawtin, Rachael E, Lee, Percy, Li, Xiaochun, McBride, William H, Schaue, Dörthe, Vanpouille-Box, Claire   +10 more
core   +1 more source

A case of de novo psoriasis induced by atezolizumab in a patient with advanced lung cancer [PDF]

, 2019
Shigeruko Iijima, Kunihiko Miyazaki, Shinya Sato, Takahide Kodama   +3 more
openalex   +1 more source

CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG) [PDF]

, 2020
Annick Desjardins, Dina Randazzo, Vidya Chandramohan, Katherine B. Peters, Margaret Johnson, Daniel Landi, Mustafa Khasraw, Stevie Threatt, Chevelle Bullock, James E. Herndon, Eric Lipp, John H. Sampson, Allan H. Friedman, Henry S. Friedman, David M. Ashley, Darell D. Bigner   +15 more
openalex   +1 more source

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

Hepatology Research, EarlyView.
In this real‐world post‐ICI setting, cabozantinib demonstrated meaningful clinical activity even at reduced doses, with disease control achieved in nearly half of patients. Importantly, preserved liver function (Child–Pugh class A) was the only determinant of both disease control and overall survival.
Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi, Mizuki Ariga, Sayaka Morisaki, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka   +13 more
wiley   +1 more source

Inmunoterapia como tratamiento del cáncer de mama [PDF]

, 2019
El cáncer de mama es el cáncer más frecuente en mujeres y suele ser de buen pronóstico si se diagnostica en etapas tempranas. Aún así, es la primera causa de muerte por cáncer en mujeres españolas.
Nagore Mejía, Adela Teresa
core  

[89Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models [PDF]

, 2023
Adriana V. F. Massicano, Patrick N. Song, Ameer Mansur, Sharon L. White, Anna G. Sorace, Suzanne E. Lapi   +5 more
openalex   +1 more source

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

International Journal of Dermatology, EarlyView.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly, Gregg Murray, Orla M Fitzpatrick, Hebatalla Ismail, Gavin P Dowling, Gargi Roy, David Synnott, Maggie O'Connor, Bryan T Hennessy, Oscar Breathnach, Liam Grogan, Megan Greally, Adrian Murphy, Patrick G Morris, Karen Eustace, Muireann Roche, Stephen Madden, Jarushka Naidoo   +17 more
wiley   +1 more source

A Rare Case of Immune‐related Adverse Events Localized to the Small Intestine

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Enterocolitis is a common gastrointestinal manifestation of immune‐related adverse events (irAEs); however, only a few studies have reported on irAE enteritis with localized active inflammation in the small intestine. Here, we report the case of a 74‐year‐old man who developed diarrhea, abdominal pain, and oral intake difficulty and was ...
Ryo Morikawa, Ryosuke Kanaya, Hiromichi Shimizu, Masayoshi Fukuda, Yasuhiro Nemoto, Toshimitsu Fujii, Towako Taguchi, Kurara Yamamoto, Kazuo Ohtsuka, Ryuichi Okamoto   +9 more
wiley   +1 more source